Healthcare -
Biotechnology - NASDAQ - US
$ 5.16
0.978 %
$ 284 M
Market Cap
-1.54
P/E
1. INTRINSIC VALUE
Balance Sheet
Verastem, Inc.
| Current Assets | 95 M |
| Cash & Short-Term Investments | 88.8 M |
| Receivables | 200 K |
| Other Current Assets | 5.94 M |
| Non-Current Assets | 6.58 M |
| Long-Term Investments | 0 |
| PP&E | 1.44 M |
| Other Non-Current Assets | 5.14 M |
| Current Liabilities | 31 M |
| Accounts Payable | 4.03 M |
| Short-Term Debt | 1.99 M |
| Other Current Liabilities | 25 M |
| Non-Current Liabilities | 99.5 M |
| Long-Term Debt | 41.3 M |
| Other Non-Current Liabilities | 58.2 M |
EFFICIENCY
Earnings Waterfall
Verastem, Inc.
| Revenue | 10 M |
| Cost Of Revenue | 26 K |
| Gross Profit | 9.97 M |
| Operating Expenses | 125 M |
| Operating Income | -115 M |
| Other Expenses | 15.7 M |
| Net Income | -131 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Verastem, Inc.
| Net Income | -131 M |
| Depreciation & Amortization | 26 K |
| Capital Expenditures | -28 K |
| Stock-Based Compensation | 7.34 M |
| Change in Working Capital | 3.72 M |
| Others | 21.7 M |
| Free Cash Flow | -105 M |
Wall Street Analysts Price Targets
Verastem, Inc.
Wall Street analysts predict an average 1-year price target for VSTM of $10.3 , with forecasts ranging from
a
low of
$7 to a high of $14 .
VSTM Lowest Price Target
Wall Street Target
7 USD
35.66%
VSTM Average Price Target
Wall Street Target
10.3 USD
100.26%
VSTM Highest Price Target
Wall Street Target
14 USD
171.32%
4. DIVIDEND
ANALYSIS
VSTM does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Verastem, Inc.
Sold
0-3 MONTHS
693 K USD 4
3-6 MONTHS
13.3 K USD 4
6-9 MONTHS
56.4 K USD 4
9-12 MONTHS
12.3 K USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Verastem: The Market Is Ignoring The Progress
FDA approval of AVMAPKI FAKZYNJA CO-PACK marks a transformative milestone, positioning Verastem as a commercial-stage leader in KRAS-mutant LGSOC treatment. Verastem's strong cash position and promising pipeline, including VS-7375 for KRAS G12D, offer significant upside with multiple near-term catalysts ahead. Risks include slow commercial uptake, pipeline uncertainty, and potential future dilution, but current valuation under $5 presents an attractive entry point.
seekingalpha.com
- 1 week ago
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the primary analysis of the Phase 2 RAMP 201 clinical trial was published online in the Journal of Clinical Oncology (JCO). The data reported in the publication showed that avutometinib plus defactinib demonstrated a confirmed overall response rate (ORR) of 31% in all patients with recurrent low-grade.
businesswire.com
- 2 weeks ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 45,000 shares of its common stock to four new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c).
businesswire.com
- 2 weeks ago
Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that updated results from the Phase 1/2 FRAME study conducted by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust were published online in Nature Medicine. The full manuscript, titled “Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial,” w.
businesswire.com
- 3 weeks ago
Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers
Recent pipeline updates highlight promising new product candidates advancing to late-stage trials, strengthening my confidence in future growth. The company maintains a solid financial position, with strong cash reserves and prudent expense management supporting ongoing R&D initiatives. Key strengths include a diversified portfolio and robust clinical data, though regulatory risks and competition remain notable challenges.
seekingalpha.com
- 1 month ago
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in VS-7375-101, the U.S. Phase 1/2a clinical trial evaluating VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, in patients with advanced KRAS G12D mutant solid tumors. “We continue to make strong progress against our strategic priorities and key mil.
businesswire.com
- 1 month ago
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as VS-7375 in the U.S.). As of May 16, 2025, 23 efficacy-evaluable patients with pancreatic ductal adenocarcinoma (PDAC) and 12 efficacy-evaluable patients with non-small cell lung cancer (NSCLC) achieved an overall.
businesswire.com
- 1 month ago
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.
zacks.com
- 1 month ago
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 4:20 pm ET in New York. A live webcast of the fireside chat can be accessed under “Events & Presentations” on the Company's website at www.verastem.com. A.
businesswire.com
- 1 month ago
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the front-line for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). As of April 25, 2025, patients in the dose level 1.
businesswire.com
- 2 months ago
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a companion diagnostic (CDx) test with Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers. Tempus completed confirmatory testing in Verastem's Phase 2 RAMP-201 clinical trial, which evaluated the combinati.
businesswire.com
- 2 months ago
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for the first quarter ended March 31, 2025. “In the first quarter of 2025, we continued to make progress with our pipeline programs by exercising our option early to license VS-7375 from our partner GenFleet Therapeutics, completing enrollment in the initial c.
businesswire.com
- 2 months ago
8. Profile
Summary
Verastem, Inc. VSTM
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 284 M
Dividend Yield
0.00%
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Contact
117 Kendrick Street, Needham, MA, 02494
https://www.verastem.com
IPO
Date
Jan. 27, 2012
Employees
78
Officers
Ms. Cathy Carew
Chief Organizational Effectiveness Officer
Ms. Colleen Mockbee
Global Head of Regulatory Affairs & Development
Dr. Robert A. Weinberg Ph.D.
Co-Founder & Chair of Scientific Advisory Board
Mr. Michael Crowther
Chief Commercial & Strategy Officer
Mr. Matthew E. Ros
Chief Operating Officer
Mr. Daniel Calkins
Chief Financial Officer
Dr. Jonathan Pachter Ph.D.
Chief Scientific Officer
Mr. Nate Sanburn
Chief Business Officer
Mr. Daniel W. Paterson
President, Chief Executive Officer & Director
Dr. Michelle Detwiler M.D., Ph.D.
Co-Founder